| Literature DB >> 32907512 |
Andrey A Toropov1, Alla P Toropova1, Aleksandar M Veselinović2, Danuta Leszczynska3, Jerzy Leszczynski4.
Abstract
The main protease (Mpro) of SARS-associated coronavirus (SARS-CoV) had caused a high rate of mortality in 2003. Current events (2019-2020) substantiate important challenges for society due to coronaviruses. Consequently, advancing models for the antiviral activity of therapeutic agents is a necessary component of the fast development of treatment for the virus. An analogy between anti-SARS agents suggested in 2017 and anti-coronavirus COVID-19 agents are quite probable. Quantitative structure-activity relationships for SARS-CoV are developed and proposed in this study. The statistical quality of these models is quite good. Mechanistic interpretation of developed models is based on the statistical and probability quality of molecular alerts extracted from SMILES. The novel, designed structures of molecules able to possess anti-SARS activities are suggested. For the final assessment of the designed molecules inhibitory potential, developed from the obtained QSAR model, molecular docking studies were applied. Results obtained from molecular docking studies were in a good correlation with the results obtained from QSAR modeling.Entities:
Keywords: Coronavirus; Monte Carlo method; Severe Acute Respiratory Syndrome; anti-SARS agents; index of ideality of correlation; molecular docking
Mesh:
Substances:
Year: 2020 PMID: 32907512 PMCID: PMC7544941 DOI: 10.1080/07391102.2020.1818627
Source DB: PubMed Journal: J Biomol Struct Dyn ISSN: 0739-1102
The statistical characteristics of the developed model for SARS-CoV Mpro inhibitory activities for three random splits of data.
| Split | Set | ||||||
|---|---|---|---|---|---|---|---|
| 1 | Active training set | 0.6464 | 0.4450 | 0.7852 | 0.956 | 0.795 | |
| Passive training set | 0.7586 | 0.5802 | 0.8205 | 0.886 | 0.610 | ||
| Calibration set | 0.9115 | 0.8512 | 0.9026 | 0.9539 | 0.470 | 0.371 | |
| Validation set | 0.9566 | 0.9320 | 0.9216 | 0.542 | 0.438 | ||
| 2 | Active training set | 0.7439 | 0.5840 | 0.8531 | 0.893 | 0.762 | |
| Passive training set | 0.7654 | 0.6003 | 0.7366 | 1.07 | 0.714 | ||
| Calibration set | 0.9174 | 0.8799 | 0.9358 | 0.9577 | 0.413 | 0.336 | |
| Validation set | 0.9442 | 0.9154 | 0.9479 | 0.454 | 0.309 | ||
| 3 | Active training set | 0.6983 | 0.4234 | 0.8223 | 0.824 | 0.650 | |
| Passive training set | 0.8445 | 0.7742 | 0.5553 | 1.54 | 1.33 | ||
| Calibration set | 0.9124 | 0.8829 | 0.9081 | 0.9548 | 0.345 | 0.267 | |
| Validation set | 0.9175 | 0.8916 | 0.9249 | 0.489 | 0.403 |
IIC = index of ideality of correlation (Toropova & Toropov, 2019); RMSE = root mean squared error; MAE = mean absolute error.
Promoters of increase and decrease of the inhibitory activity of SARS‐CoV Mpro (IC50, μM).
| No. | SMILES attribute | CWs Probe 1 | CWs Probe 2 | CWs Probe 3 | N1 | N2 | N3 |
|---|---|---|---|---|---|---|---|
| Promoters of IC50 increase | |||||||
| 1 | 2.63153 | 1.15486 | 3.78669 | 10 | 10 | 10 | |
| 2 | 2.55878 | 1.21207 | 1.64933 | 10 | 10 | 10 | |
| 3 | 0.48795 | 0.06021 | 2.20339 | 10 | 10 | 10 | |
| 4 | 2.02730 | 0.56998 | 2.44765 | 10 | 10 | 10 | |
| 5 | 0.05582 | 0.34232 | 0.34661 | 10 | 10 | 10 | |
| 6 | 0.07471 | 0.40638 | 1.18716 | 10 | 10 | 10 | |
| 7 | 2.96490 | 1.14621 | 2.40403 | 10 | 10 | 10 | |
| 8 | 0.04212 | 0.58132 | 0.22205 | 10 | 10 | 10 | |
| 9 | 0.30264 | 0.00072 | 0.28500 | 10 | 10 | 10 | |
| 10 | 1.35271 | 0.05507 | 0.12055 | 10 | 10 | 10 | |
| 11 | 0.43671 | 0.17893 | 0.17255 | 9 | 8 | 6 | |
| 12 | 1.10523 | 0.50393 | 0.47038 | 9 | 8 | 7 | |
| 13 | 0.16441 | 0.57525 | 0.88699 | 9 | 7 | 7 | |
| 14 | 0.13313 | 0.43790 | 0.28864 | 9 | 7 | 6 | |
| 15 | 0.10720 | 0.32142 | 0.33964 | 8 | 6 | 4 | |
| Promoters of IC50 decrease | |||||||
| 1 | −0.02294 | −0.17040 | −0.48815 | 6 | 3 | 4 | |
| 2 | −0.15624 | −0.05464 | −0.16157 | 3 | 2 | 0 | |
| 3 | −0.25960 | −0.10767 | −0.08532 | 3 | 2 | 0 | |
| 4 | −2.54052 | −0.12802 | −2.47903 | 2 | 0 | 0 | |
| 5 | −2.13926 | −1.32809 | −2.11675 | 1 | 3 | 1 | |
| 6 | −0.05921 | −0.10068 | −0.01523 | 1 | 1 | 2 |
N1, N2, and N3 are frequencies of molecular features in the active training set, passive training set, and calibration set, respectively; CWs are the correlation weight.
Examples of proposed modifications for structure #38 together with variations of model values of SARS-CoV Mpro inhibitory activity.
| Structures and SMILES | Model IC50[µM] | Comment |
|---|---|---|
| Basis | 0.921 | |
| Improvement | 0.850 | Fragment [N] is added |
| Improvement | 0.909 | Fragment [F] is added |
| Improvement | 0.838 | Fragments [N] and [F] are added |
Figure 1.The experimental and calculated SARS-CoV Mpro inhibitory activities for three random splits.
Score values (kcal/mol) for all computer-aided designed compounds.
| Molecule | ||||||
|---|---|---|---|---|---|---|
| A | −95.3978 | 0 | −108.245 | −31.6369 | −93.9852 | −81.9477 |
| A1 | −96.2774 | −2.5 | −109.457 | −21.6198 | −94.3305 | −78.3661 |
| A2 | −96.357 | 0 | −108.868 | −30.6175 | −94.9384 | −82.1304 |
| A3 | −97.1479 | −2.5 | −107.498 | −33.5078 | −93.8624 | −85.0888 |
Figure 2.Binding energies of the studied compound with the active site of SARS-CoV Mpro.
Figure 3.MD studies are applied to identify all interactions between the designed molecules and amino acids from SARS-CoV Mpro, including hydrogen bonds, hydrophobic, and hydrophilic interactions.